Ocugen Inc (OCGN)
$1.64
0.02 (1.20%)
OCGN Stock Quote Delayed 30 Minutes
The Hype Will Continue to Fade for Ocugen Stock
OCGN stock is pitched as a combination vaccine and biotech play. But the story isn't enough to support a valuation still well past $1 billion.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
422.02M
PE Ratio
-6.83
EPS
-0.24
Volume (Avg. Vol.)
3.12M
Day's Range
$1.60 - $1.69
52-Week Range
$0.35 - $2.11
Dividend & Yield
N/A (N/A)
OCGN Stock Predictions, Articles, and Ocugen Inc News
What Will the Stock Market Do Today? 3 Big Stories to Watch.
So what will the stock market do today? Investors are carefully scrutinizing a $2 trillion infrastructure spending bill from President Biden.
Ocugen Is a Crisis Trade That Just Might Pan Out
OCGN stock is risky yet the underlying science behind its Covid-19 vaccine combined with a messy situation in the U.S. bodes well.
Ocugen Stock Will Continue to Climb in Anticipation of Vaccine Launch
OCGN stock is the final biotech looking to make a play for Covid-19 vaccine revenue. Should investors dive in?
Why Ocugen Stock Is Just a Gamble Right Now
A recent stock surge might make OCGN stock tempting. But it's a poor choice given Ocugen's lack of predictable profitability and the general uncertainty around its future.
Is Approval Even Enough for Ocugen Stock?
Ocugen's partner has shown promise with its Covid-19 vaccine. But with Ocugen getting just 45% of U.S. profits, that promise is priced into OCGN stock.
Ocugen Stock Has Way More Downside, Even After This Deep Correction
OCGN stock looks unattractive even after a big correction from highs. Vaccine space looks crowded in the U.S. and Ocugen might not benefit.
OCGN Stock: 3 Key Catalysts That Could Send This Stock Soaring Again
Investors in OCGN stock have seen shares settle down quite a bit of late, but there's room to be optimistic with this biotech stock.
Ocugen Looks Very Dicey at Current Levels
Ocugen believes it can distribute 100 million doses of a Covid-19 vaccine in the U.S. But this looks like a long shot for OCGN stock.
Ocugen Stock Is Not One to Trust With Nest Egg Funds
There is too much riding on hope for OCGN stock. It is OK to trade it but fundamental investments are too risky for most.
Make Sure You See Ocugen Stock With Clear Eyes
OCGN stock is a hot trade at this point in 2021. But it's important for investors to see the company's outlook clearly.
Keep Your Eyes on Ocugen Stock as It May Move Back to $20 Soon
OCGN stock has swung wildly since Ocugen pivoted towards Covid-19 vaccine development, but recently reported data suggests a bright outlook.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
What did the stock market do today? Investors focused on speculative vaccine plays, cannabis stocks and reopening rallies.
OCGN Stock: Red-Hot Ocugen Eyes U.S. Vaccine Launch in Q2
OCGN stock just got a big boost. According to a new report, Ocugen plans to launch its Covid-19 vaccine in the U.S. soon.
Sell Ocugen Stock Now Before It Sinks Even Further
Biden's decision to buy 100 million more of Johnson & Johnson's vaccine, along with the potential of herd immunity, makes OCGN stock a sell.
Ocugen Needs Pieces To Fall Into Place Before It’s a Solid Vaccine Play
OCGN stock is a risky Covid-19 vaccine play which needs to pass overcome several hurdles before it can be considered a viable investment.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
What did the stock market do today? All eyes were on the Covid-19 vaccine rollout and on bad news for EV stocks.
Ocugen Stock May Have One More Rally in It Before It’s Over
Long-term prospects for OCGN stock remain unclear, but its Covid-19 catalyst could fuel another spike in the short-term.
What Will the Stock Market Do Today? 3 Big Stories to Watch.
So what will the stock market do today? All eyes are on vaccine stocks thanks to Biden's plan and Netflix is cracking down.
